Novartis Institutes for Biomedical Research, Inc., ("Novartis") has entered into a fully paid up license agreement of Housey Pharma's core-enabling technologies for new-drug discovery with HMI Medical Innovations, LLC, an affiliate of Housey Pharma (www.housey.com) . The announcement was made today by Gerard Housey, M.D., Ph.D., founder and CEO of Housey Pharma.
SOUTHFIELD, Mich., Jan. 16, 2025 /PRNewswire-PRWeb/ -- Novartis Institutes for Biomedical Research, Inc., ("Novartis") has entered into a fully paid up license agreement of Housey's core-enabling technologies for new-drug discovery with HMI Medical Innovations, LLC, an affiliate of Housey Pharma (www.housey.com) . The announcement was made today by Gerard Housey, M.D., Ph.D., founder and CEO of Housey Pharma.
Scientists at Housey Pharma have developed the next generation of drug-discovery technology in the cell-based assay field. Cell-based assay systems are research tools that use living cells engineered to identify and refine new medicines. Housey Pharma's technologies are being offered for licensure on a non-exclusive basis to other research-based pharmaceutical companies worldwide through an affiliate, HMI Medical Innovations, LLC.
According to Dr. Housey, one of the co-inventors of the technology, the platform enables the creation of target-specific, cell-based assay systems using technologies in genetic engineering, biochemistry and cell-biology. It is especially well-suited for targets previously thought to be "undruggable" in the human genome. Scientists often describe certain targets in the human body as "undruggable targets" to reflect the extreme difficulty of creating or discovering a medicine capable of therapeutically modulating their biological function. "Undruggable targets are operative in many human diseases, including drug-resistant cancers, diabetes, neurodegenerative disorders like dementia, and many others," said Dr. Housey.
The licensed drug-discovery platform technology has been awarded 17 issued patents with more than 195 issued claims in the United States as well as dozens of other countries worldwide, with more pending. The technology includes methods of discovering compounds that overcome drug-resistant cancers, generalized drug discovery and lead- optimization methods applicable to all human diseases, and certain compounds. The technology is particularly applicable to the discovery and development of protein kinase inhibitors useful for the treatment of drug-resistant cancers.
"We are pleased to include a leading edge innovator like the Novartis Institutes for Biomedical Research as a paid-up Licensee" said Dr. Housey. "Breakthroughs in the discovery and development of new medicines have been made through the use of this advanced technology platform by our scientific colleagues at our many licensees, including Novartis."
Other noteworthy licensees of these technologies from HMI include Bristol Myers Squibb, Hoffmann La Roche, the Janssen Pharmaceutical division of Johnson & Johnson, and others."
About Housey Pharma and HMI Medical Innovations, LLC
Housey Pharma is a commercial stage, privately held biopharmaceutical company engaged in the discovery, research, development and sale of medicines that address important, unserved medical and health needs. Housey Pharma's products are created through the application of advanced, patented and proprietary drug discovery technologies invented at the company. Its affiliate, HMI Medical Innovations provides access to this core enabling technology platform to the research based pharmaceutical industry. HMI believes that its patented technologies comprise a core-enabling platform that provides licensees with a competitive advantage for new drug discovery and creation.
For more information, visit www.housey.com.
Media Contact
Thomas Klema, Housey Pharmaceutical Research Laboratories, LLC, 1 2486637000 252, [email protected], Housey Pharmaceutical Research Laboratories, LLC
SOURCE Housey Pharmaceutical Research Laboratories, LLC
Share this article